Volume 33 · Issue 3 · September 2023

Psychiatry and Clinical Psychopharmacology



EISSN 2475-0581

psychiatry-psychopharmacology.com

Volume 33 | Issue 3 | September 2023 psychiatry-psychopharmacology.com

Editor in Chief

Mesut Cetin Emeritus Professor of GATA Haydarpaşa Training Hospital, Istanbul, Turkey

Deputy Editor

Feyza Arıcıoğlu Marmara University, Istanbul, Turkey

Section Editors

Glen Baker University of Alberta, Edmonton, Canada

Altay Burak Dalan Yeditepe University, İstanbul, Turkey

Rasim Somer Diler University of Pittsburg, Pittsburg, USA

Serdar Dursun University of Alberta, Edmonton, Canada

Andrew Greenshaw University of Alberta, Edmonton, Canada

Marek Kubicki Harvard Medical School, Boston, USA

Mihriban Heval Özgen LUMC, Leiden University, Leiden, The Netherlands

Anita Riecher-Rössler University of Basel, Basel, Switzerland

Gianluca Serafini Department of Neuroscience, San Martino Hospital (IRCCS), Genoa, Italy

Bayram Yılmaz Yeditepe University, İstanbul, Turkey

Associate Editors

Ömer Avdemir Department of Psychiatry, Celal Bayar University School of Medicine, Manisa, Turkey

Leslie Citrome New York Medical College, New York, USA

Yuan-Hwa Chou Veterans General Hospital, Taipei, Taiwan

Christoph U. Correll Charité University Medicine, Berlin, Germany



Founder İbrahim KARA

General Manager Ali SAHİN

Finance Coordinator Elif YILDIZ ÇELİK

Ted Dinan University College Cork, Dublin, Ireland

Cüneyt Evren Department of Psychology, İstanbul Gelişim University, İstanbul, Turkey

Vahdet Görmez Medeniyet University, Istanbul, Turkey

Kvooseob Ha National University College of Medicine, Seoul, South Korea

Angelos Halaris Loyola University, Chicago, USA

Jaime Eduardo Hallak University of São Paulo, São Paulo, Brazil

Kenji Hashimoto Chiba University Center for Forensic Mental Health, Division of Clinical Neuroscience, Chiba, Japan

Carsten Hjorthøj Copenhagen Research Center for Mental Health, Copenhagen, Denmark

Hans W Hoek University Medical Center Groningen, Groningen, The Netherlands

Matcheri Keshavan Harvard Medical School, Boston, USA

Yong-Ku Kim College of Medicine, Korea University, Seoul, South Korea

Brian Leonard Emeritus Professor, National University, Galway, Ireland

Mingli Li Sichuan University, Sichuan, China

Tao Li Sichuan University, Sichuan, China

Xin Min Li Alberta University, Edmonton, Canada

Qing Ma University at Buffalo, Buffalo, USA

Norbert Muller Ludwig-Maximilian-University, Munich, Germany

> Journal Managers İrem SOYSAL Deniz KAYA

Gökhan ÇİMEN Alara ERĜİN İrem ÖZMEN Derva AZER Beril TEKAY

Kerim Munir Harvard Medical School, Boston, USA

David Osser Harvard Medical School, Boston, USA

Dost Öngür Harvard Medical School, Boston, USA

Vedat Sar Department of Psychiatry, Koç University School of Medicine, İstanbul, Turkey

Lut Tamam Department of Psychiatry, Çukurova University School of Medicine, Adana, Turkey

Paul Thompson University of Southern California, USA

Ali Evren Tufan Department of Child and Adolescent Psychiatry, Abant İzzet Baysal University, School of Medicine, Bolu, Turkey

Erdem Tüzün Department of Neuroscience, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkey

Willem van den Brink Amsterdam University Medical Centers, Amsterdam, The Netherlands

Allan Young King's College, London, UK

Editorial Board

Adam Abba-Aji University of Alberta, Edmonton, Canada

Yasser Ad-Dab'bagh King Fahad Specialist Hospital, Dammam, Saudi Arabia

Mohammad Saleh Alghamdi University of Alberta, Edmonton, Canada

José Alexandre de Souza Crippa University of São Paulo, São Paulo, Brazil

Rafael Guimarães dos Santos University of São Paulo, São Paulo, Brazil

> **Project Coordinators** Doğan ORUÇ Sinem Fehime KOZ

Project Assistant Batuhan Kara

Onur Burak Dursun Republic of Turkey, Ministry of Health, Ankara, Turkey

Sugai Liang Sichuan University, Sichuan, China

Yuping Ning Guangzhou Brain Hospital, Guangzhou, China

David Nutt Imperial College, London, UK

Jim Van Os Utrecht University Medical Centre, Utrecht, The Netherlands

Mücahit Öztürk Ibn Haldun University, Istanbul, Turkey

Kemal Sayar Marmara Úniversity, Istanbul, Turkey

Carol Tamminga UT Southwestern Medical Center, Dallas, USA

Massimo Tusconi University of Cagliari, Cagliari, Italy

Patricia Zunszain King's College, London, UK

Ethics Editor

Gürkan Sert Department of Medical History and Ethics, Marmara University, School of Medicine, İstanbul, Turkey

Biostatistics Editor

İlker Ercan

Uludağ University, School of Medicine, Department of Biostatistics, Bursa, Turkey

> Contact Address: Büyükdere Cad. 199/6, 34394, Şişli, İstanbul, Türkiye Phone: +90 212 217 17 00 E-mail: info@avesyayincilik.com

Irmak BERBEROĞLU ARZU ARI **Publication Coordinators**

Volume 33 | Issue 3 | September 2023 psychiatry-psychopharmacology.com

About the Psychiatry and Clinical Psychopharmacology

Psychiatry and Clinical Psychopharmacology is a peer reviewed, open access, online-only journal.

Psychiatry and Clinical Psychopharmacology is a quarterly journal that is published in English in March, June, September, and December. Psychiatry and Clinical Psychopharmacology is supported by the Turkish Association for Psychopharmacology.

Journal History

As of 2016, the journal has changed its title to Psychiatry and Clinical Psychopharmacology.

Current Title (2017 - ...) Psychiatry and Clinical Psychopharmacology EISSN: 2475-0581

Previous Title (1990-2017) Klinik Psikofarmakoloji Bülteni – Bulletin of Clinical Psychopharmacology ISSN: 1302-9657 EISSN: 1302-9657

Abstracting and Indexing

Psychiatry and Clinical Psychopharmacology is covered in the following abstracting and indexing databases;

- Science Citation Index Expanded
- Scopus
- DOAJ
- Embase
- Gale
- CNKI
- HINARI
- Proquest: Proquest Psychology Journals
- Proquest Health&Medical Complete
- EBSCO
- · Chemical Abstracts (CAS)
- TUBITAK ULAKBIM TR Index

All content published in the journal is permanently archived in Portico.

Aims, Scope, and Audience

Psychiatry and Clinical Psychopharmacology aims to publish studies of the highest scientific and clinical value, and encourages the submission of high-quality research that advances the understanding scientific fields such as psychiatry, child and adolescent psychiatry, neuroscience, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, neuroimaging, artificial intelligence, machine learning, neuronal networks, and related sciences.

Psychiatry and Clinical Psychopharmacology covers a wide range of topics related to psychiatry and clinical psychopharmacology as well as forming a scientific forum by producing quality debate on various disciplines. The journal is interested in publishing original research that addresses important clinical questions and advances the understanding and treatment of these conditions. This may include studies on psychiatry, child and adolescent psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, neuroimaging, artificial intelligence, machine learning, neuronal networks, and related sciences.

Psychiatry and Clinical Psychopharmacology publishes original research, reviews, case reports, letters to the editors, editorials, and short communications/ brief reports within its scope. Conference proceedings may also be considered for publication.

The target audience of the journal includes specialists, residents, and scientists in psychiatry, psychology, neurology, neuroscience, pharmacology, molecular biology, genetics, physiology, neurochemistry, and related disciplines.

Open Access Policy

Psychiatry and Clinical Psychopharmacology is an open access publication.

Starting on March 2021, all content published in the journal is licensed under the Creative Commons Attribution-NonCommercial (CC BY-NC) 4.0 International License which allows third parties to read and share the material immediately upon publication for only non-commercial purposes by giving the appropriate credit to the original work. Adaptation and modification of the material is not permitted.

The content published before March 2021 was licensed under a traditional copyright, but the archive is still available for free access.

All published content is available online, free of charge at https://psychiatry-psychopharmacology.com/.

Authors retain unrestricted copyrights and publishing rights in Psychiatry and Clinical Psychopharmacology.

Volume 33 | Issue 3 | September 2023 psychiatry-psychopharmacology.com

When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

Copyright Policy

A Copyright Agreement and Acknowledgement of Authorship form should be submitted with all manuscripts. By signing this form, authors agree that the article, if accepted for publication by the Psychiatry and Clinical Psychopharmacology, will be licensed under a Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC 4.0) which allows third parties to read and share the material immediately upon publication for only non-commercial purposes by giving the appropriate credit to the original work. Adaptation and modification of the material is not permitted.

When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

Authors retain unrestricted copyrights and publishing rights in Psychiatry and Clinical Psychopharmacology.

Publication Fee Policy

Psychiatry and Clinical Psychopharmacology is funded by article processing charges (APC).

The article processing charge for the journal is 590 USD (updated in February 2021). Apart from the APC, there are no other fees or surcharges associated with the evaluation or publication process.

Authors are required to properly disclose any financial support they receive for the payment of the article processing charge.

Disclaimer

The statements or opinions expressed in the manuscripts published in the journal reflect the views of the author(s) and not the views of the editors, editorial board, and/or publisher. The editors, editorial board, and publisher are not responsible for the content of the manuscripts and do not necessarily endorse the views expressed in them. It is the responsibility of the authors to ensure that their work is accurate and well-researched, and the views expressed in their manuscripts are their own. The editors, editorial board, and publisher simply provide a platform for the authors to share their work with the scientific community.

You can find the current version of the Instructions to Authors at: https://psychiatry-psychopharmacology.com/en/instructions-to-authors-1020

Editor in Chief: Mesut Cetin, M.D., Professor of Psychiatry Address: Bagdat Caddesi Birgen Plaza 226/7 Kadikoy 34728 Istanbul, Turkey Mobile & Whatsapp: +90-532-272-3252 psikofarmakoloji@gmail.com

Publisher: AVES Address: Büyükdere Cad. 199/6, 34394, Şişli, İstanbul, Türkiye Phone: +90 212 217 17 00 E-mail address: info@avesyayincilik.com www.avesyayincilik.com

Volume 33 | Issue 3 | September 2023 psychiatry-psychopharmacology.com

CONTENTS

ORIGINAL ARTICLES

- **156** Risk of Relapse Assessment Scale for Metamphetamine Abusers: Reliability and Validity Study of the Turkish Version Çetin Turan, Ersin Budak, Güliz Şenormancı, Cüneyt Evren, Süheyla Ünal, Elvan Açıkgöz Yalçınkaya, Ömer Senormanci
- 163 Satisfaction of Patients and Their Relatives Who Are Reminded of Their Appointments and Treatments with "Treatment Collaboration Portal" Meryem Gül Teksin, Ersin Hatice Karshoğlu, Yasemin Arıkoğlu, Ali Çayköylü
- 170 Erythrocytic Reduced/Oxidized Glutathione and Serum Thiol/Disulfide Homeostasis in Patients with Opioid Use Disorder Esra Kabadayı Şahin, Almila Şenat, İbrahim Söğüt, Tomris Duymaz, Özcan Erel
- 177 Adaptation of the Attitudes Toward Motherhood Scale to Turkish: Reliability and Validity Study Kumru Şenyasar Meterelliyoz, Menekşe Sıla Yazar, Perihan Çobanoğlu Saf, Coşkun Saf
- 187 The Potential Use of Monocyte-to-High-Density Lipoprotein Ratio as a Chronic Inflammatory Marker in Major Depressive Disorder Onur Öztürk, Ayşe Pınar Doğru Balakbabalar, Muhammed Okuyucu, Muhammed Emin Göktepe
- 193 Functional Impairments and Related Factors in Adolescents with Attention Deficit Hyperactivity Disorder During the COVID-19 Normalization Stage Esen Yıldırım Demirdöğen, Mehmet Akif Akıncı, Abdullah Bozkurt, Ali Çakır, Çiğdem Tanrıverdi
- 203 Perceived Social Support and Parental Emotional Temperament Among Children with Attention Deficit and Hyperactivity Disorder Mutlu Muhammed Özbek, Doğa Sevinçok, Hatice Aksu
- 211 Serum Zonulin and Claudin-5 but not Interferon-Gamma and Interleukin-17A Levels Increased in Children with Specific Learning Disorder: A Case–Control Study

Yaşar Tanır, Abdurrahman Cahid Örengül, Yahya Esad Özdemir, Ali Karayağmurlu, Tuba Bilbay Kaynar, Adile Merve Baki, Pervin Vural, Murat Coşkun

CASE REPORT

218 Sertraline-Induced Leukocytoclastic Vasculitis with Definite Causal Association: A Case Report Mahmut Selçuk

REVIEW

222 The Psychotherapy of Schizophrenia: A Review of the Evidence for Psychodynamic and Nonpsychodynamic Treatments Mark L. Ruffalo

SYSTEMATIC REVIEW

229 Gray Matter Alterations in Panic Disorder: A Voxel-Wise Meta-Analysis Anguang Pan, Shaojie Liu, Shijun Hu, Jin Dai, Juan Yi